A Study Evaluating the Safety, Pharmacokinetics, and Pharmacodynamics of KA34 in Subjects With Knee Osteoarthritis
| Status: | Recruiting |
|---|---|
| Conditions: | Arthritis, Osteoarthritis (OA) |
| Therapuetic Areas: | Rheumatology |
| Healthy: | No |
| Age Range: | 40 - 75 |
| Updated: | 1/23/2019 |
| Start Date: | May 2, 2018 |
| End Date: | February 2020 |
| Contact: | Alma Villasin, RN, BSN, MBA |
| Email: | Alma.villasin@IQVIA.com |
| Phone: | +1 856 473 5374 |
A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Dose Escalation Study Evaluating the Safety, Pharmacokinetics, and Pharmacodynamics of KA34 Administered Via Intra-Articular Injection in Subjects With Osteoarthritis of the Knee
This study will evaluate the safety and tolerability of KA34 when administered via
intra-articular injection to subjects with osteoarthritis of the knee.
intra-articular injection to subjects with osteoarthritis of the knee.
Inclusion Criteria:
- Diagnosis of localized osteoarthritis of the knee
- Males willing to use contraception and females who are no longer able to bear children
Exclusion Criteria:
- Body Mass Index (BMI) > 40
- Grade 3 or 4 osteoarthritis on the Kellgren and Lawrence classification system
- Injury to the knee or other joint within the last 12 months
- Receipt of any investigational product or experimental therapeutic procedure within
the last 12 weeks
We found this trial at
4
sites
100 West Gore Street
Orlando, Florida 32806
Orlando, Florida 32806
Principal Investigator: Judith White, M.D.
Phone: 407-426-9299
Click here to add this to my saved trials
2147 Northeast Coachman Road
Clearwater, Florida 33765
Clearwater, Florida 33765
Principal Investigator: Robert Levin
Phone: 727-466-0078
Click here to add this to my saved trials
Duncansville, Pennsylvania 16635
Principal Investigator: Alan Kivitz
Phone: 814-296-6101
Click here to add this to my saved trials
Walnut creek, California 94598
Principal Investigator: Leonard Chuck
Phone: 925-930-7267
Click here to add this to my saved trials